Revlimid 2.5 mg hard capsules

DRUG7 trials

Sponsors

Celgene Corp., Glaxosmithkline Research & Development Limited, Epizyme Inc., Universita' Degli Studi Di Torino, Fondazione European Myeloma Network Italy O.N.L.U.S.

Conditions

Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLHigh-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationMultiple MyelomaNEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANTNewly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell TransplantationNewly diagnosed MM patients >= 65 years old or ineligible for autologous stem cell transplantPATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

Phase 1

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)–DREAMM5.

Active, not recruitingCTIS2023-509550-55-00

Glaxosmithkline Research & Development LimitedMultiple Myeloma

Start: 2020-01-21Target: 62Updated: 2025-10-10

Phase 2

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse

Not yet recruitingCTIS2024-518275-64-00

Instytut Hematologii I TransfuzjologiiDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL, Diffuse large B-cell lymphomas (DLBCL, High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiation

Target: 340Updated: 2025-11-24

A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as pre transplant INDUCTION and post transplant consolidation or continuous treatment with CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 cycles) without transplant, all followed by MAINTENANCE with LENALIDOMIDE (R) versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT

Active, not recruitingCTIS2024-516630-35-01

Universita' Degli Studi Di TorinoNEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT

Start: 2015-01-12Target: 477Updated: 2025-09-25

Phase 3

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruitingCTIS2022-501346-30-00

Celgene Corp.Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell Transplantation

Start: 2023-09-25Target: 332Updated: 2025-12-09

CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL (EMN20)

Active, not recruitingCTIS2024-513396-41-00

Fondazione European Myeloma Network Italy O.N.L.U.S.PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

Start: 2019-05-15Target: 340Updated: 2025-12-15

SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

RecruitingCTIS2024-510690-16-00

Epizyme Inc.Relapsed/refractory follicular lymphoma

Start: 2022-01-31Target: 226Updated: 2025-06-26

Phase 4

A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) – Real MM

Active, not recruitingCTIS2024-512049-17-00

Universita' Degli Studi Di TorinoNewly diagnosed MM patients >= 65 years old or ineligible for autologous stem cell transplant

Start: 2018-09-05Target: 450Updated: 2025-12-05